What is Celexa (Citalopram)?
Celexa (citalopram hydrobromide) is a selective serotonin reuptake inhibitor (SSRI) antidepressant FDA-approved for the treatment of major depressive disorder in adults. 1
Medication Overview
Celexa is a racemic bicyclic phthalane derivative SSRI with a chemical structure distinct from other SSRIs, tricyclics, and tetracyclics 1. It is available as:
- Oral tablets: 10 mg, 20 mg, and 40 mg strengths
- Oral solution: 2 mg/mL concentration
The medication contains citalopram HBr with various inactive ingredients including copolyvidone, corn starch, lactose monohydrate, and magnesium stearate 1.
FDA-Approved Indication
Celexa is specifically indicated for treating major depressive disorder (MDD), defined as a prominent and persistent depressed or dysphoric mood lasting nearly every day for at least 2 weeks that interferes with daily functioning 1. The diagnosis requires at least five of nine DSM criteria including: depressed mood, anhedonia, significant weight/appetite changes, sleep disturbances, psychomotor changes, fatigue, guilt/worthlessness, concentration difficulties, or suicidal ideation 1.
Efficacy was established in 4-6 week controlled trials, and maintenance of antidepressant response was demonstrated for up to 24 weeks in placebo-controlled continuation trials 1.
Clinical Characteristics
Pharmacological Profile
Citalopram is recognized as the most selective serotonin reuptake inhibitor among SSRIs 2. It demonstrates:
- High selectivity for serotonin reuptake inhibition
- Minimal effect on other neurotransmitter systems
- Lower propensity for CYP450-mediated drug interactions compared to other SSRIs (particularly less effect on CYP2D6 than fluoxetine, paroxetine, or sertraline) 3
Dosing Parameters
- Standard therapeutic range: 20-40 mg daily 4
- Maximum dose: 40 mg/day (general population)
- Maximum dose in elderly (>60 years): 20 mg/day due to QT prolongation risk 3, 5
- Dose titration: Increase at 1-2 week intervals for shorter half-life SSRIs like citalopram 3
Critical Safety Considerations
QT Prolongation Warning
Citalopram carries a significant risk of dose-dependent QT interval prolongation, which can lead to Torsade de Pointes, ventricular tachycardia, and sudden death 3. This risk is particularly pronounced:
- At daily doses exceeding 40 mg
- In patients older than 60 years (maximum 20 mg/day)
- When combined with other QT-prolonging medications
- In patients with long QT syndrome (contraindicated) 3
The FDA and EMA issued warnings limiting maximum doses specifically due to QT studies demonstrating this cardiac risk 5.
Drug Interactions
Absolute contraindication: Concomitant use with monoamine oxidase inhibitors (MAOIs) due to serotonin syndrome risk 3
Exercise caution with:
- Other QT-prolonging drugs (especially critical for citalopram) 3
- Multiple serotonergic agents (SSRIs, SNRIs, TCAs, tramadol, meperidine, methadone, fentanyl, dextromethorphan, St. John's wort, tryptophan) 3
- When combining, start the second agent at low dose and monitor closely in first 24-48 hours after dosage changes 3
Common Adverse Effects
Typical SSRI side effects include 4:
- Nausea (most common reason for discontinuation)
- Somnolence or insomnia
- Dry mouth
- Increased sweating
- Sexual dysfunction
- Dizziness
- Headache
Discontinuation Syndrome
While citalopram has a lower risk of discontinuation syndrome compared to paroxetine, fluvoxamine, or sertraline 3, abrupt cessation can still cause dizziness, fatigue, nausea, sensory disturbances, and anxiety. Taper over 10-14 days when discontinuing 6.
Special Populations
Elderly Patients
Citalopram is considered a preferred agent for older adults with depression 4 due to:
- Favorable adverse effect profile
- Lower anticholinergic effects than paroxetine
- Less activation than fluoxetine
However, strict dose limitation to 20 mg/day maximum is mandatory in patients >60 years due to increased QT prolongation risk 3, 5.
Hepatic/Renal Impairment
Pregnancy and Lactation
Citalopram transfers to breast milk, with potential adverse effects in infants (irritability, decreased feeding) documented in case reports, though causality is not firmly established 4. Sertraline and paroxetine produce lower infant plasma concentrations 4.
Comparative Effectiveness
All second-generation antidepressants, including citalopram, demonstrate equivalent efficacy for treatment-naive patients with major depression 4. Medication selection should prioritize:
- Adverse effect profile
- Drug interaction potential
- Patient-specific factors (age, comorbidities, cardiac risk)
- Cost and dosing convenience
Citalopram's primary advantage is its lower drug interaction potential compared to other SSRIs 3, making it suitable when polypharmacy is necessary, though this must be balanced against its unique cardiac risk profile 3, 5.
Clinical Efficacy Context
Antidepressants demonstrate greatest benefit in patients with severe depression compared to mild-moderate depression 4. The STAR*D trial found that patients most likely to achieve remission with citalopram were those with shorter episode duration and less severe baseline depression 4.